Increased Thalamocortical Connectivity in Schizophrenia Correlates With Sleep Spindle Deficits: Evidence for a Common Pathophysiology.


Journal

Biological psychiatry. Cognitive neuroscience and neuroimaging
ISSN: 2451-9030
Titre abrégé: Biol Psychiatry Cogn Neurosci Neuroimaging
Pays: United States
ID NLM: 101671285

Informations de publication

Date de publication:
08 2019
Historique:
received: 06 02 2019
revised: 06 04 2019
accepted: 24 04 2019
pubmed: 3 7 2019
medline: 28 3 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

Converging evidence implicates abnormal thalamocortical interactions in the pathophysiology of schizophrenia. This evidence includes consistent findings of increased resting-state functional connectivity of the thalamus with somatosensory and motor cortex during wake and reduced spindle activity during sleep. We hypothesized that these abnormalities would be correlated, reflecting a common mechanism: reduced inhibition of thalamocortical neurons by the thalamic reticular nucleus (TRN). The TRN is the major inhibitory nucleus of the thalamus and is abnormal in schizophrenia. Reduced TRN inhibition would be expected to lead to increased and less filtered thalamic relay of sensory and motor information to the cortex during wake and reduced burst firing necessary for spindle initiation during sleep. Overnight polysomnography and resting-state functional connectivity magnetic resonance imaging were performed in 26 outpatients with schizophrenia and 30 demographically matched healthy individuals. We examined the relations of sleep spindle density during stage 2 non-rapid eye movement sleep with connectivity of the thalamus to the cortex during wakeful rest. As in prior studies, patients with schizophrenia exhibited increased functional connectivity of the thalamus with bilateral somatosensory and motor cortex and reduced sleep spindle density. Spindle density inversely correlated with thalamocortical connectivity, including in somotosensory and motor cortex, regardless of diagnosis. These findings link two biomarkers of schizophrenia-the sleep spindle density deficit and abnormally increased thalamocortical functional connectivity-and point to deficient TRN inhibition as a plausible mechanism. If TRN-mediated thalamocortical dysfunction increases risk for schizophrenia and contributes to its manifestations, understanding its mechanism could guide the development of targeted interventions.

Sections du résumé

BACKGROUND
Converging evidence implicates abnormal thalamocortical interactions in the pathophysiology of schizophrenia. This evidence includes consistent findings of increased resting-state functional connectivity of the thalamus with somatosensory and motor cortex during wake and reduced spindle activity during sleep. We hypothesized that these abnormalities would be correlated, reflecting a common mechanism: reduced inhibition of thalamocortical neurons by the thalamic reticular nucleus (TRN). The TRN is the major inhibitory nucleus of the thalamus and is abnormal in schizophrenia. Reduced TRN inhibition would be expected to lead to increased and less filtered thalamic relay of sensory and motor information to the cortex during wake and reduced burst firing necessary for spindle initiation during sleep.
METHODS
Overnight polysomnography and resting-state functional connectivity magnetic resonance imaging were performed in 26 outpatients with schizophrenia and 30 demographically matched healthy individuals. We examined the relations of sleep spindle density during stage 2 non-rapid eye movement sleep with connectivity of the thalamus to the cortex during wakeful rest.
RESULTS
As in prior studies, patients with schizophrenia exhibited increased functional connectivity of the thalamus with bilateral somatosensory and motor cortex and reduced sleep spindle density. Spindle density inversely correlated with thalamocortical connectivity, including in somotosensory and motor cortex, regardless of diagnosis.
CONCLUSIONS
These findings link two biomarkers of schizophrenia-the sleep spindle density deficit and abnormally increased thalamocortical functional connectivity-and point to deficient TRN inhibition as a plausible mechanism. If TRN-mediated thalamocortical dysfunction increases risk for schizophrenia and contributes to its manifestations, understanding its mechanism could guide the development of targeted interventions.

Identifiants

pubmed: 31262708
pii: S2451-9022(19)30108-9
doi: 10.1016/j.bpsc.2019.04.012
pmc: PMC6688951
mid: NIHMS1528782
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

706-714

Subventions

Organisme : NIMH NIH HHS
ID : K24 MH099421
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH067720
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH092638
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH048832
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR023043
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR023401
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR019307
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007901
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Références

Brain Res. 1980 Nov 3;200(2):341-54
pubmed: 7417821
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
J Neurosci Methods. 2007 Aug 15;164(1):177-90
pubmed: 17517438
Brain Stimul. 2015 May-Jun;8(3):567-73
pubmed: 25862600
J Neurochem. 1999 Oct;73(4):1590-7
pubmed: 10501205
Nat Methods. 2014 Apr;11(4):385-92
pubmed: 24562424
Clin EEG Neurosci. 2008 Apr;39(2):82-6
pubmed: 18450174
J Psychiatr Res. 2010 Jan;44(2):112-20
pubmed: 19665729
Nature. 2004 Dec 9;432(7018):758-61
pubmed: 15592414
Nature. 2017 May 11;545(7653):219-223
pubmed: 28467827
J Psychiatr Res. 2010 Jan;44(1):42-7
pubmed: 19559446
Front Hum Neurosci. 2014 Oct 07;8:762
pubmed: 25339881
Nat Neurosci. 2011 Jul 24;14(9):1118-20
pubmed: 21785436
Eur Arch Psychiatry Clin Neurosci. 2017 Apr;267(3):213-224
pubmed: 27565806
Nat Neurosci. 2003 Jul;6(7):750-7
pubmed: 12808459
Sci Rep. 2019 Feb 27;9(1):2952
pubmed: 30814558
Front Neural Circuits. 2016 Jan 05;9:83
pubmed: 26778969
Am J Psychiatry. 2007 Mar;164(3):483-92
pubmed: 17329474
J Comp Neurol. 2003 Sep 1;463(4):360-71
pubmed: 12836172
Schizophr Bull. 2011 Mar;37(2):238-43
pubmed: 21307040
Sleep Med. 2015 May;16(5):564-9
pubmed: 25912599
Neuroimage. 2007 Aug 1;37(1):90-101
pubmed: 17560126
Neural Plast. 2016;2016:5787423
pubmed: 27293903
Schizophr Bull. 2014 Nov;40(6):1227-43
pubmed: 25031221
J Neurosci. 2009 Aug 5;29(31):9930-40
pubmed: 19657043
Psychol Med. 2018 Nov;48(15):2492-2499
pubmed: 29444726
Am J Psychiatry. 2010 Nov;167(11):1339-48
pubmed: 20843876
J Physiol. 1996 Jan 1;490 ( Pt 1):159-79
pubmed: 8745285
Nature. 2006 Nov 30;444(7119):610-3
pubmed: 17086200
Cereb Cortex. 2014 Dec;24(12):3116-30
pubmed: 23825317
Curr Biol. 2016 Aug 22;26(16):2127-36
pubmed: 27476602
Schizophr Bull. 2015 Mar;41(2):522-31
pubmed: 25074975
Biol Psychiatry. 2016 Oct 15;80(8):599-608
pubmed: 26602589
Magn Reson Med. 2000 Sep;44(3):457-65
pubmed: 10975899
Sci Rep. 2016 Oct 19;6:34233
pubmed: 27756899
Am J Psychiatry. 2012 Oct;169(10):1092-9
pubmed: 23032387
Am J Psychiatry. 2001 Sep;158(9):1393-9
pubmed: 11532723
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):111-9
pubmed: 23892770
Biol Psychiatry. 2015 Jun 15;77(12):1071-8
pubmed: 25680672
Neurosci Biobehav Rev. 2011 Apr;35(5):1154-65
pubmed: 21167865
Neural Plast. 2016;2016:3024342
pubmed: 27144033
Front Behav Neurosci. 2015 Feb 25;9:45
pubmed: 25762911
Mol Psychiatry. 2018 Oct;23(10):2057-2065
pubmed: 29180672
Nature. 2016 Apr 7;532(7597):58-63
pubmed: 27007844
Sleep Med Rev. 2003 Oct;7(5):423-40
pubmed: 14573378
Biol Psychiatry. 2012 Jan 15;71(2):154-61
pubmed: 21967958
Magn Reson Med. 2003 Nov;50(5):1077-88
pubmed: 14587019
Eur J Neurosci. 2011 Oct;34(7):1031-9
pubmed: 21895800
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
Neuroimage. 2005 Aug 1;27(1):222-30
pubmed: 15886023
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18583-8
pubmed: 23091013
Neuron. 2018 Apr 18;98(2):282-295
pubmed: 29673480
J Neurosci. 2013 Mar 6;33(10):4494-504
pubmed: 23467365
Brain Imaging Behav. 2018 Jun;12(3):640-652
pubmed: 28444556
Neurosci Lett. 2006 Jul 31;403(1-2):52-6
pubmed: 16714084
Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13823-8
pubmed: 21808016
J Neurosci. 2005 Oct 12;25(41):9398-405
pubmed: 16221848
J Neurosci. 2012 Apr 11;32(15):5250-63
pubmed: 22496571
Neuroimage. 2012 Jan 16;59(2):1420-8
pubmed: 21889994
Cell. 2014 Aug 14;158(4):808-821
pubmed: 25126786
J Neurophysiol. 2010 Jan;103(1):297-321
pubmed: 19889849
Trends Neurosci. 1993 Jun;16(6):240-5
pubmed: 7688166
Schizophr Res. 2017 Feb;180:58-63
pubmed: 27531067
Neurosci Biobehav Rev. 2015 Aug;55:78-87
pubmed: 25956256
Neuroimage. 2012 Jan 2;59(1):431-8
pubmed: 21810475
Neuroscience. 1998 Jul;85(2):331-45
pubmed: 9622234
Brain Res Brain Res Rev. 2004 Aug;46(1):1-31
pubmed: 15297152
Brain Res. 2000 Dec 15;886(1-2):208-223
pubmed: 11119697
J Cogn Neurosci. 2013 Oct;25(10):1597-610
pubmed: 23767926
PLoS Comput Biol. 2010 Jun 10;6(6):e1000808
pubmed: 20548945
Science. 1996 Nov 1;274(5288):771-4
pubmed: 8864114
JAMA Psychiatry. 2015 Sep;72(9):882-91
pubmed: 26267151
Front Biosci. 2003 May 01;8:d878-99
pubmed: 12700074
J Neurophysiol. 2001 Sep;86(3):1365-75
pubmed: 11535683
Magn Reson Med. 2012 Aug;68(2):389-99
pubmed: 22213578

Auteurs

Bengi Baran (B)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.

Fikret Işık Karahanoğlu (FI)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.

Dimitrios Mylonas (D)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.

Charmaine Demanuele (C)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.

Mark Vangel (M)

Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts; Department of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Robert Stickgold (R)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Alan Anticevic (A)

Department of Psychiatry, Yale University, New Haven, Connecticut.

Dara S Manoach (DS)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts. Electronic address: Dara.Manoach@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH